City of Hope National Medical Center /ID# 277005, Duarte
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928, Irvine
UC San Diego Health - Moores Cancer Center /ID# 278836, La Jolla

Vključevanje udeležencevFaza 2/3

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07155187

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

City of Hope Comprehensive Cancer Center, Duarte
University of California Los Angeles, Los Angeles
University of California San Diego Moores Cancer Center, San Diego

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06625775

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Tower Cancer Research Foundation, Beverly Hills
Kaiser Permanente Dublin, Dublin
Kaiser Permanente-Fremont, Fremont
in še 20

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06498635

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site, Santa Rosa

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06996782

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Center 9, La Jolla
ALX Center 11, Santa Monica

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07085091

Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

Stanford University, Stanford

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT04585490

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Beverly Hills Cancer Center, Beverly Hills
Orange Coast Memorial Medical Center, Fountain Valley
Local Institution - 0027, Los Alamitos
in še 5

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07361510

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

START LA, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
Valkyrie Clinical Trials, Los Angeles

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07659782

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Hoag Hospital Newport Beach, Newport Beach
University of California, Irvine Health, Orange

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06765109

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Duarte
Research Site, Los Angeles
Research Site, Newport Beach
in še 1

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT05877599

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Providence - St. Jude Medical Center /ID# 271414, Fullerton
FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard
UCLA - Santa Monica /ID# 271690, Santa Monica

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

MemorialCare Long Beach Medical Center, Long Beach

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06881784

A Study of PHN-012 in Patients With Advanced Solid Tumors

PHN-012-001 Site, Los Angeles
PHN-012-001 Site, San Diego

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07127874

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Alta Bates Summit Medical Center Comprehensive Cancer Center, Berkeley
John Muir Health Clinical Research Center, Concord
UC San Diego Medical Center - Encinitas, Encinitas
in še 16

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07144280

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

University of California at San Diego, La Jolla
University of California Irvine, Orange
Stanford Cancer Institute, Stanford

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05498428

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

City of Hope, Duarte
City of Hope 1, Irvine

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07586202

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Beverly Hills Cancer Center ( Site 0070), Beverly Hills
UCLA Clinical & Translational Research Center (CTRC) ( Site 0033), Los Angeles
Hoag Memorial Hospital Presbyterian ( Site 0096), Newport Beach
in še 2

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Oncura Health - Anaheim, Anaheim
Memorial Care Orange Coast Medical Center Attn, Fountain Valley
MemorialCare Orange Coast Medical Center, Fountain Valley
in še 20

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07222566

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Sansum Clinic, Santa Barbara

Vključevanje udeležencevFaza 3

Starost 18–100 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05920356

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Duarte
Research Site, Los Angeles
Research Site, Newport Beach

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06218914

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Stanford Cancer Institute, Stanford
Stanford Hospital and Clinics, Stanford
Stanford Hospital Investigational Drug Services, Stanford

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07489066

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

University of California San Diego, La Jolla
Stanford University, Palo Alto
UCLA Medical Center, Santa Monica

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT04981119

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Providence Medical Foundation, Fullerton
Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
Providence St. Jude Medical Center, Fullerton
in še 1

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The Oncology Institute of Hope and Innovation, Cerritos
City of Hope Corona, Corona
City of Hope, Duarte
in še 26

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

The City of Hope Orange County Lennar Foundation Cancer Center, Irvine

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07154290

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Moores Cancer Center at UC San Diego Health, La Jolla

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667908

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130), Burbank

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06170788

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Providence Medical Foundation, Fullerton
Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
Providence St. Jude Medical Center, Fullerton
in še 9

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07227298

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.